Layman, R. M., Jerzak, K. J., Hilton, J. F., Ortega, P. T., Bueno, A. M., Chia, S. K., Bellet, M., Chien, J., Chappey, C., Wang, H., Lonning, S., Berkowitz, N. C., Zhang, Y., Kleha, J. F., Ma, C. X. (2026). Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus abemaciclib (ABE) in ER+/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): TACTIVE-U phase 1b/2 results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1067